# ScinoPharm Taiwan, Ltd.
# 2021 Annual General Shareholders' Meeting Minutes
# (Translation)

Time and Date: 10:00a.m., Tuesday, July 21, 2021

Place: ScinoPharm Taiwan, Ltd. (Corporate Site)
1 Nan-Ke 8th Road, Southern Taiwan Science Park, Shan-Hua, Tainan, Taiwan

Attendants: All shareholders and their proxy holders, representing 603,469,554 shares (among them 540,772,977 shares voted via electronic transmission), or 76.32% of the total 790,739,222 outstanding shares.

Chairperson: Chih-Hsien Lo Recorder: Jane Liu

Directors Present: Chairman Chih-Hsien Lo、Tsung-Ming Su、
Wei-Te Ho (independent director- Chairman of the Audit committee)

Directors Attended Online: Po-Ming Hou、Tsung-Pin Wu、Fu-Jung Lai、Jia-Horng Guo、
Chiou-Ru Shih、Kuo-Hsi Wang、Ming-Chuan Hsieh、Ya-Po Yang、
Wen-Chang Chang(Independent director)、Lewis Lee (independent director newly elected at 2021 Annual General Shareholders' Meeting)

Attendees: Yung-Chih Lin (CPA), Albert Fang (Attorney)

The aggregate shareholding of the shareholders presents in person or by proxy constituted a quorum. The chairman called the meeting to order.

## A. Chairperson's address (omitted)

## B. Report Items

(1). 2020 Business Report.

Explanation: The business report for 2020 is attached as Appendix 1.

(2). Audit Committee's Review Report on 2020 Financial Results.

Explanation: The Audit Committee Review's Report for 2020 is attached as Appendix 2.

(3) 2020 Compensations for Employees and Directors.

Explanation:

a. The remuneration distribution for employees and directors on 2020 is calculated according to Article 40 of the Articles of Incorporation: "Should the Company earn surpluses within the current term, at least two percent of surpluses should be set aside for employees' compensation, and no more than two percent of surpluses should be set aside for directors' compensation…".

b. According to the Articles of Incorporation, the employees' compensation for 2020 was NT$35,288,214, making up 8.91% of the year's profits; directors' compensation was NT$7,921,843, making up 2% of the year's profits; all compensation was distributed in cash. The aforementioned amounts differed from accrued amounts by 0 for both employees' compensation and directors' compensation.

(4) Proposed Amendments to the Rules of Procedure for Board of Directors Meeting of the Company.

Explanation:

a. According to the revised "Sample Template for OO Co., Ltd. Rules of Procedure for Board of Directors Meeting" publicized by Taiwan Stock Exchange on June. 3rd, 2020, plus in consideration of practical operation, revised the company's Rules of Procedure for Board of Directors Meeting.

b. Major points of the revision include: addition of Q1, Q2, Q3, and Annual financial reports approved by the chairman, CEO and chief accountant with signatures or chops to items mandatory for discussion at the board of directors and removal of the regulations on time limit on deferral of meeting, discussion of items on agenda, and principles for adjournment.

c. Please refer to Appendix 3 of Contrast Table of the Rules of Procedure for Board of Directors Meeting of the Company.

## C Ratification Items

(1) Ratification of 2020 Business Report and Financial Statements. (Proposed by the Board)

Explanation:

a. The Parent and Consolidated Financial Statements for 2020 of the Company as adopted by the March 18, 2021 meeting of the Board of Directors and duly certified by Yung-Chih Lin, Certified Public Accountant and Tzu-Meng Liu, Certified Public Accountant from PricewaterhouseCoopers Taiwan were duly submitted in conjunction with the Business Report to the Audit Committee for inspection. This inspection was completed with the Auditors Committee's Review Reports duly issued.

b. Please see Appendix 1 and Appendices 4~5 for the Business Report, Auditors' Reports, parent and consolidated financial statements.

Voting Result –
Shares represented at the time of voting: 603,469,554

| Voting Results* | | % of the total represented share present |
|---|---|---|
| Votes in favor: | 601,131,801 votes<br>(538,435,224 votes) | 99.61% |
| Votes against: | 168,381 votes<br>(168,381 votes) | 0.02% |
| Abstained votes／No vote: | 2,169,372 votes<br>(2,169,372 votes) | 0.37% |
| Votes invalid | 0 votes | 0% |

*including votes casted electronically (numbers in brackets)

RESOLVED, that the above proposal be and hereby was approved as proposed.

(2) Ratification of the Proposed Distribution of 2020 Earnings. (Proposed by the Board)

Explanation:

a. The 2020 Profit Allocation Proposal is attached as Appendix 6.

b. The Company's distributable earnings for 2020 are NT$648,248,261. The cash dividend to be distributed is NT$0.5 per share. Upon the approval of the General Shareholders' Meeting, it is proposed that the Board of Directors be authorized to resolve the ex-dividend date, payment date, and adjust the dividends to be distributed to each share based on the number of actual shares outstanding on the record date for distribution.

c. Cash dividends paid to each individual shareholder will be rounded down to the nearest dollar. Fractional shares with a value less than one dollar are accumulated and reported as the Company's other income.

Voting Result –
Shares represented at the time of voting: 603,469,554

| Voting Results* | | % of the total represented share present |
|---|---|---|
| Votes in favor: | 601,105,861 votes<br>(538,409,284 votes) | 99.60% |
| Votes against: | 192,381 votes<br>(192,381 votes) | 0.03% |
| Abstained votes／<br>No vote: | 2,171,312 votes<br>(2,171,312 votes) | 0.37% |
| Votes invalid | 0 votes | 0% |

*including votes casted electronically (numbers in brackets)

RESOLVED, that the above proposal be and hereby was approved as proposed.

## D. Discussion Items

(1) Proposed Amendments to the Rules of Procedures for Shareholders' Meeting of the Company. (Proposed by the Board)

Explanation:

a. According to the revised "Sample Template for XXX Co., Ltd. Rules of Procedure for Shareholders' Meeting," publicized by Taiwan Stock Exchange, decree No. 11000014461, on Jan. 28, 2021, plus in consideration of practical operation, revised Rules of Procedures for Shareholders' Meeting of the Company.

b. The revision is to uphold corporate governance and shareholders' interests, including:

(1). The chairperson of the meeting shall announce to commence the meeting in due course and publicize information on both the number of shares without voting right and number of shares in attendance.

(2). The election (if any) of the director(s) of the Company at the shareholders meeting shall be in accordance with the relevant bylaw of the Company and the result of the election shall be announced at the meeting including the name of each director elect and the amount of votes for them each. List of directors not elected and the amount of votes they obtain should also be announced.

c. Please refer to Appendix 7 of Contrast Table of Rules of Procedures for Shareholders' Meeting of the Company

d. It is proposed that resolution be adopted for the authorization proposed above.

Voting Result –
Shares represented at the time of voting: 603,469,554

| Voting Results* | | % of the total represented share present |
|---|---|---|
| Votes in favor: | 601,185,805 votes<br>(538,489,228 votes) | 99.62% |
| Votes against: | 121,381 votes<br>(121,381 votes) | 0.02% |
| Abstained votes／<br>No vote: | 2,162,368 votes<br>(2,162,368 votes) | 0.36% |
| Votes invalid | 0 votes | 0% |

*including votes casted electronically (numbers in brackets)

RESOLVED, that the above proposal be and hereby was approved as proposed.

## E. **Election**

(1) The 10th Election of Board of Directors (including independent directors) (Proposed by the Board).

Explanation:

a. The office term of the 9$^{th}$ Election of Board of Directors is from June 27$^{th}$ 2018 to June 26$^{th}$ 2021.

b. It is proposed that fifteen Directors (including three Independent Directors) should be elected in accordance with the Articles of Incorporation of the Company. According to Article 195 of the Company Act, in the event that the office term of the 9$^{th}$ election of Board of Directors (including Independent Directors) is completed prior to the 10$^{th}$ election, the Directors should continue to exercise their office duties until stepping down upon assumption of office by the new Board of Directors. The Directors newly elected shall forthwith assume the office upon being elected and serve an office term of three years from the election date, namely from July 21 2021 through July 20 2024.

c. Article 23 of the Articles of Incorporation of the Company states that two or more of the above Directors shall be Independent Directors, and the total number of Independent Directors shall account for not less than one fifth (1/5) of the total number of directors. The Directors (including Independent Directors) shall be elected under the nomination system. Shareholders' Meeting shall elect from among the candidates nominated.

d. According to article 24 of Articles of Incorporation and article 14-4 of Securities and Exchange Act, all independent directors comprise the auditing committee. Therefore, the forth auditing committee comes into being and becomes operational following the election of new independent directors.

e. Please see Appendix 8 for the name list of the candidates nominated as adopted by the meeting of May 11, 2021 of the Board of Directors.

f. Shareholders are requested to vote to elect the new Directors.

Result: Elected Board Directors Name list

(1) Directors: Twelve seats

| Shareholder No. | Name | Representative | Votes received |
|---|---|---|---|
| 4 | Uni-President Enterprises Corp. | Chih-Hsien Lo | 966,106,006 |
| 4 | Uni-President Enterprises Corp. | Tsung-Ming Su | 871,563,156 |
| 1 | National Development Fund, Executive Yuan | Ming-Chuan Hsieh | 834,416,820 |
| 1 | National Development Fund, Executive Yuan | Ya-Po Yang | 834,202,144 |
| 5 | Tainan Spinning Co., Ltd. | Po-Ming Hou | 546,414,681 |
| 860 | Kao Chyuan Investment Co., Ltd | Shiow-Ling Kao | 541,346,412 |
| 4 | Uni-President Enterprises Corp. | Jia-Horng Guo | 510,616,507 |
| 4 | Uni-President Enterprises Corp. | Tsung-Pin Wu | 500,853,760 |
| 2 | Taiwan Sugar Corporation | Kuo-Hsi Wang | 500,277,935 |
| 861 | President International Development Corp. | Chiou-Ru Shih | 492,347,961 |
| 4 | Uni-President Enterprises Corp. | Fu-Jung Lai | 490,496,590 |
| 4 | Uni-President Enterprises Corp. | Chin-Yuan Cheng | 481,980,981 |

(2) Independent Directors：Three seats

| Name | Votes received |
|---|---|
| Lewis Lee | 478,957,650 |
| Wen-Chang Chang | 478,867,022 |
| Li-Tzong Chen | 478,822,921 |

The number of Invalid votes was 0

## F. **Other Proposals**

(1) Proposed release the Directors (including Independent Directors) elected and their representatives from non-competition restrictions. (Proposed by the Board)

Explanation:

a. According to Article 209 of the Company Act, the Director who intends to do any act or activity which is within the scope of the Company's business for himself/herself or for any other person shall present to the Shareholders' Meeting an explanation of the substantial content of the act or activity contemplated and obtain the approval of the Shareholders' Meeting for him/her to do the act or activity and the Shareholders' Meeting may adopt the resolution.

b. In consideration that the members of the 10th Election of Board of Directors (including independent directors) may do any act or activity and concurrently hold another office within the scope of the Company's business, it is proposed that resolution be adopted to release the newly elected 10th Election of Board of Directors from the non-compete restriction provided in Article 209 of the Company Act on the precondition that the above act or activity done by the director does not in any way prejudice the interests of the Company.

c. Titles and job details of directors (including independent directors) who will be exempting from non-compete competition prohibition as show in Appendix 9.

d. It is proposed that resolution be adopted for the authorization proposed above.

Voting Result –

Shares represented at the time of voting: 603,469,554

| Voting Results* | | % of the total represented share present |
|---|---|---|
| Votes in favor: | 601,093,354 votes<br>(538,396,777 votes) | 99.60% |
| Votes against: | 190,065 votes<br>(190,065 votes) | 0.03% |
| Abstained votes／<br>No vote: | 2,186,135 votes<br>(2,186,135 votes) | 0.37% |
| Votes invalid | 0 votes | 0% |

*including votes casted electronically (numbers in brackets)

RESOLVED, that the above proposal be and hereby was approved as proposed.

## G. Extemporary motions

## H. Meeting adjourned

**Appendix 1**

# ScinoPharm Taiwan, Ltd.
# 2020 Business Report

In 2020, the whole world was severely impacted by COVID-19. It was a very difficult year for all industries. COVID-19 started off as a regional epidemic found only in China, and soon spread to the rest of the world resulting in border lockdowns. The World Health Organization has also officially defined COVID-19 as a pandemic. All these changes are affecting and influencing wide range of industries in a persistent manner. ScinoPharm, however, at the face of the highly uncertain global market, maintained consistently healthy operations against the adverse conditions last year, and kept moving forward in accordance with its strategic deployment, achieving set targets of revenue and profit. By doing so, the company manifested its resilience and business strength in quickly adapting itself to the environment.

The company's consolidated revenue for 2020 was NT$3.083 billion, net profit after tax was NT$282 million, and after-tax earnings per share was NT$0.36. As of the end of 2020, the company's paid-up capital was $7.907 billion, and shareholder's equity $10.529 billion, which accounted for approximately 89% of its total assets of $11.847 billion; long-term capital 2.65 times the value of its fixed assets, with a current ratio of 8.62, maintaining a sound and healthy financial structure.

**Maintaining stable operations and continuing to build up its strength to cope with challenges**

In general, the clients' demand for API products continued to grow last year. However, due to the impact of COVID-19 prevention policies and measures in various locations, global logistics and transportation was in an extraordinary period, with restricted import and export channels, resulting in a delay by suppliers of main raw materials in performing their contracts to service certain manufacturing processes. This has hindered the production and sales of API products to a certain extent. Due to completion of pre-production works such as material preparation in the year before, coupled with the properly adapted production schedule as well as sales and transportation planning, the company has managed to keep its scheduled production activities and sales substantially unaffected for the first half of the year, despite the enhancing isolation, border control, distancing or split team rotational arrangements at different stages in different countries to contain the virus. However, starting from the second half of the year, with the aggressively accelerated impact of COVID-19 on the US market, and the sign of its return as a mutated version, countries led by the United States have become more actively involved in the research and development of vaccines and products that might become therapeutic drugs. As a result, some customers re-adjusted their shipment schedules, to which the company also adapted its production and sales planning. The performance of outsourced R&D services has benefited from the flexible sales strategies, periodic stocking requirements and the customers' great ambitions in developing products to address new indications, becoming a highlight of last year's business performance.

**The process of new product launch accelerates vertical integration and synergies of synchronized development**

On the part of development of the API business, ScinoPharm's Changshu plant, for the first time last year, underwent the onsite inspection by the China National Medical Products Administration for the first time for food and drug registration, and the China GMP compliance inspection for two items. It is expected to be approved for marketing in China this year. This product is an emergency medicine against rare diseases, for which there is currently no alternative treatment. Once the marketing license has been obtained, large-scale commercial production will be carried out; and customers are optimistic about the market potential of this product and it is expected to become the one of the knock-out products of Changshu plant going forward. This year in China, it is expected that three more products developed in partnership with customers will go through the dynamic verification with the regulatory authorities, and the company remains optimistic about the prospects and development of the China market. Progress has also been made in the development of injectable products. The company’s first home developed and manufactured injectable generic peptide product has been put through to the US Food and Drug Administration for review and approval. The strategy of extending the life cycle of existing products through vertical integration is in gradual implementation. Crossing over into complex injectable products is the first step of ScinoPharm’s business expansion. In the future, it will not only continue to invest in the R&D and production of injectable products and establish strategic alliances that will be additive and multiplicative to seize the injection market; and it is also optimistic about the potential of the oral administration market, seeking to open up a brand new space in the highly competitive pharmaceutical industry.

**Attaching importance to organizational safety with continuous review and management of operational risks**

In order to maintain a safe and sound workplace, the company has always applied a high standard to and involved the entire staff in safety management, with ongoing review of the existing safe work process for compliance with the current requirements, and checking on whether the process has been carefully implemented. To enhance industrial safety and environmental protection, considerable manpower and funds are being invested as planned. Last year saw the phase two expansion of the warehouse and transformation of the dangerous when wet warehouse. Old pipelines that have reached the end of service life are replaced and improved, with the addition of monitoring systems and waste treatment equipment, enhanced safety inspections and audits, and upgraded protection equipment for production and operation, in an effort to comprehensively improve protection, industrial safety and discipline. The goal is to maintain effective control over and to reduce fire and explosion caused by unpredictable natural disasters, earthquakes, use of solvent and high-risk operations, or personal injuries caused by insufficient protection and operational errors. The company attaches great importance to safety and never compromises. It is a basic requirement to implement safety regulations, and the highest guiding principle and goal to totally eliminate industrial safety incidents attributable to man.

**Adhering to quality standards in pursuit of a perfecting quality culture**

As a member of the global pharmaceutical supply chain, "Compliance and Legal" is the basic requirement for the manufacture process and quality of products. In order to ensure product quality, efficacy and the safety of drug users, the company has consistently applied the most prudent management approach to the development and production of every product, with spirit of never giving up. Since the establishment of the company, the existing organizational structure and management system are already well established. It is another challenge as to how to continuously and seamlessly implement the existing quality management structure, promptly adapt itself to changes in the laws and regulations of different jurisdictions, and enhance the implementation of knowledge management and the carry-forward of experience. We firmly believe it is the responsibility of the wider company to implement our quality culture. We proactively advocate the development of thinking and behaviors necessary to maintain high quality standards internally, and build up a solid quality culture for the company.

**Keeping track of the market and working hard to achieve corporate goals**

Looking ahead to 2021, in the face of the continued impact and shock of the pandemic and the rapidly evolving industry, it is reasonable to expect that the company's operations will continue to come across many challenges. There will always be challenges, and it depends on adequate preparations at ordinary times to be able to respond quickly to crises. Emergencies test the company's ability to take risks, and also reflect the health of the company. With the new year ahead, ScinoPharm will still overcome difficulties with a positive attitude. The management team of ScinoPharm will also be aligned on their goals and continue to lead all colleagues to take steady steps forward. We believe that with the efforts of our colleagues and the persistent support of the shareholders, we will continue to strengthen the foundation of stable operations, seize the opportunities from demands of the global pharmaceutical market and abide by industrial regulations and quality standards, to improve corporate profitability in order to reward the shareholders, customers and colleagues.

Chih-Hsien Lo, Chairman

**Appendix 2**

# Audit Committee's Review Report

The Board of Directors has prepared the Company's 2020 Business Report, Parent and Consolidated Financial Statements, and proposal for allocation of profits. The CPA firm of PricewaterhouseCoopers Taiwan was retained to audit the Company's Financial Statements and has issued an audit report relating to the Financial Statements. The Business Report, Financial Statements, and profit allocation proposal have been reviewed and determined to be correct and accurate by the Audit Committee members of ScinoPharm Taiwan, Ltd. According to Article 14-4 of the Securities and Exchange Act and Article 219 of the Company Act, we hereby submit this report.

ScinoPharm Taiwan, Ltd.

Chairman of the Audit Committee: Wei-Te Ho

March 18, 2021

**Appendix 3**

## ScinoPharm Taiwan, Ltd.

## Proposed amendments to the Rules of Procedure for Board of Directors Meeting

| Current Provision | Revision Proposed | Remark |
|---|---|---|
| **Article 5** (Units in charge of meeting and Meeting Material)<br>The board of directors has designated the two divisions of Administrative Management and Financial Accounting to take charge of meeting affairs jointly.<br>Units in charge of meeting affairs should formulate contents for the agenda of meetings of the board of directors and provide sufficient meeting materials, to be delivered along with meeting notice.<br>(Omitted) | **Article 5** (Units in charge of meeting <u>affairs</u> and Meeting Material)<br>The board of directors has designated the two divisions of Administrative Management and Financial Accounting to take charge of meeting affairs jointly.<br>Units in charge of meeting affairs should formulate contents for the agenda of meetings of the board of directors and provide sufficient meeting materials, to be delivered along with meeting notice.<br>(Omitted) | Revise title, in conformance to the contents of the article |
| **Article 7** (Matters required to be submitted to the meeting of the Board of Directors)<br>The following matters must be proposed to the meeting of the Board of Directors for discussion:<br>1. Business plan of the Company.<br>2. Annual financial report <u>and semi-annual financial report except where the semi-annual financial report is not legally required to be certified by the accountants.</u><br>(Omitted) | **Article 7** (Matters required to be submitted to the meeting of the Board of Directors)<br>The following matters must be proposed to the meeting of the Board of Directors for discussion:<br>1. Business plan of the Company.<br>2. <u>addition of Q1, Q2, Q3, and Annual financial reports approved by the chairperson, CEO and chief accountant with signatures or chops</u><br>(Omitted) | Revise the text of the item 1-2 of the article, in line with the revision made on June 21, 2019 of No.10, item 1, of article 14-5 of Securities and Exchange Act and corporate practice. |
| **Article 10: Non-director attendees and principle for announcing beginning of meeting**<br>When the board of directors is convened, the general affairs unit for meeting should prepare related data as reference for directors.<br>For convening of board of directors, related units or subsidiaries can be notified for sending representatives to attend the meeting, so can the certified public account, attorney at law, or other professionals. Those outside attendees, however, should leave, during discussion and voting.<br>At scheduled time and with attendance | **Article 10: Non-director attendees and principle for announcing beginning of meeting**<br>When the board of directors is convened, the general affairs unit for meeting should prepare related data as reference for directors.<br>For convening of board of directors, related units or subsidiaries can be notified for sending representatives to attend the meeting, so can the certified public account, attorney at law, or other professionals. Those outside attendees, however, should leave, during discussion and voting.<br>At scheduled time and with attendance | Remove said contents, in line with the revision of the reference sample publicized by the competent authority. |

| Current Provision | Revision Proposed | Remark |
|---|---|---|
| of over half of directors, chairman should announce starting of meeting. If there are less than half of directors in attendance at scheduled time, chairman can postpone the starting of meeting, twice for one hour at maximum, otherwise, chairman should reschedule the meeting, according to item 2, article 3.<br>The so-called all the directors, as mentioned in the previous item and item2-2, article 15, refer to all the directors in office. | of over half of directors, chairman should announce starting of meeting. If there are less than half of directors in attendance at scheduled time, chairman can postpone the starting of meeting twice at maximum, chairman should reschedule the meeting, according to item 2, article 3.<br>The so-called all the directors, as mentioned in the previous item and item2-2, article 15, refer to all the directors in office. | |
| **Article 11** (Discussion and announcement of meeting adjourned)<br>The meeting of the Board of Directors shall proceed according to the agenda indicated in the meeting notice unless otherwise changed by the majority of the directors present at the meeting. The chairperson must not announce the meeting adjourned before the agenda provided in the preceding paragraph and the extempore motions proposed to the meeting are duly discussed and resolved except otherwise approved by the majority of the directors present at the meeting.<br>During the proceeding of the meeting, where the directors present falls short of one half of the total number of directors, the chairperson shall, on the motion proposed by the director present at the meeting, announce the meeting suspended, in which case paragraph three of Article 10 of these Rules shall apply with necessary and appropriate alterations. | **Article 11** (Discussion and announcement of meeting adjourned)<br>The meeting of the Board of Directors shall proceed according to the agenda indicated in the meeting notice unless otherwise changed by the majority of the directors present at the meeting. The chairperson must not announce the meeting adjourned except otherwise approved by the majority of the directors present at the meeting.<br>During the proceeding of the meeting, where the directors present falls short of one half of the total number of directors, the chairperson shall, on the motion proposed by the director present at the meeting, announce the meeting suspended, in which case paragraph three of Article 10 of these Rules shall apply with necessary and appropriate alterations. | Remove said contents, in line with the revision of the reference sample publicized by the competent authority. |
| **Article 19: Implementation & Revision**<br>These Rules were established on 25 September 2009 and subsequently revised as follows: 1st revision of 26 March 2012, 2nd revision of 14 December 2012, 3rd revision of December 19, 2017, 4th revision of March 20 2020. | **Article 19: Implementation & Revision**<br>These Rules were established on 25 September 2009 and subsequently revised as follows: 1st revision of 26 March 2012, 2nd revision of 14 December 2012, 3rd revision of December 19, 2017, 4th revision of March 20 2020, 5th revision of March 18,2021. | In line with the revision, add the revision date to the text. |

## Appendix 4

INDEPENDENT AUDITORS' REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of ScinoPharm Taiwan, Ltd.

### *Opinion*

We have audited the accompanying parent company only balance sheets of ScinoPharm Taiwan, Ltd. (the "Company") as at December 31, 2020 and 2019, and the related parent company only statements of comprehensive income, of changes in equity and of cash flows for the years then ended, and notes to the parent company only financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying parent company only financial statements present fairly, in all material respects, the financial position of the Company as at December 31, 2020 and 2019, and its financial performance and cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

### *Basis for opinion*

We conducted our audits in accordance with the Regulations Governing Auditing and Attestation of Financial Statements by Certified Public Accountants and generally accepted auditing standards in the Republic of China. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the parent company only financial statements section of our report. We are independent of the Company in accordance with the Norm of professional Ethics for Certified Public Accountants in the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### *Key audit matters*

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Company's 2020 parent company only financial statements. These matters were addressed in the context of our audit of the parent company only financial statements as a whole and, in forming our opinion thereon, we do not provide a separate opinion on these matters.

The key audit matters for the Company's 2020 parent company only financial statements are stated as follows:

### *Cutoff of export revenue*

Description

Refer to Note 4(28) to the parent company only financial statements for accounting policy on revenue recognition and Note 6(18) to the parent company only financial statements for accounting items on revenue.

The Company's sales revenue mainly arises from the manufacture and sales of Active Pharmaceutical Ingredient ("API"), which primarily consists of export sales. The Company recognises export sales revenue based on the terms and conditions of transactions which vary with different customers. As revenue recognition involves manual processes and is material to the financial statements, we consider the cutoff of export revenue a key audit matter.

How our audit addressed the matter

We performed the following key audit procedures in response to the above key audit matter:

1. Understood and assessed the effectiveness of internal controls over cutoff of sales revenue and tested the effectiveness of internal controls over shipping and billing.
2. Checked the completeness of the export sales details for a certain period around balance sheet date and performed cutoff tests on a random basis, which included checking the terms and conditions of transactions, verifying against supporting documents, and checking whether inventory movements and costs of sales were recognised in the appropriate period.

***Inventory valuation***

Description

Refer to Note 4(11) for accounting policies on inventory valuation, Note 5(2)1 for the uncertainty of accounting estimates and assumptions applied in inventory valuation, and Note 6(4) for details of inventories. As at December 31, 2020, the balances of inventory and allowance for inventory valuation losses were $1,448,766 thousand and $313,819 thousand, respectively.

The Company is primarily engaged in the manufacture and sales of API. As the manufacturing process is relatively complicated and time-consuming, materials require longer lead time, the waiting period for product registration is long, and the timing of the product launch may be deferred, there is higher risk of incurring loss on inventory valuation. For inventories sold under normal terms, the Company measures inventories at the lower of cost and net realisable value. For inventories aging over a certain period of time and are individually identified as obsolete inventories, the net realisable value is calculated based on the historical information of inventory turnover. Since the calculation of net realisable value involves subjective judgement and the ending balance of inventory is material to the financial statements, we consider the valuation of inventory a key audit matter.

How our audit addressed the matter

We performed the following key audit procedures in response to the above key audit matter:

1. Evaluated the reasonableness of provision policies and procedures on allowance for inventory valuation losses, including the historical data of inventory turnover and judgement of obsolete inventory.
2. Verified whether the dates used in the inventory aging reports that the Company applied to value inventories were accurate. Recalculated and evaluated the reasonableness of allowance for inventory valuation losses in order to confirm whether the reported information was in line with the Company's policies.
3. Selected samples from inventory items by each sequence number to verify its realisable value and to evaluate the reasonableness of allowance for inventory valuation loss.

***Responsibilities of management and those charged with governance for the parent company only financial statements***

Management is responsible for the preparation and fair presentation of the parent company only financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and for such internal control as management determines is necessary to enable the preparation of parent company only financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the parent company only financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including audit committee, are responsible for overseeing the Company's financial reporting process.

***Auditors' responsibilities for the audit of the parent company only financial statements***

Our objectives are to obtain reasonable assurance about whether the parent company only financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the generally accepted auditing standards in the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these parent company only financial statements.

As part of an audit in accordance with the generally accepted auditing standards in the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the parent company only financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the parent company only financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.

5. Evaluate the overall presentation, structure and content of the parent company only financial statements, including the disclosures, and whether the parent company only financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient appropriate audit evidence regarding the financial information of the Company to express an opinion on the parent company only financial statements. We are responsible for the direction, supervision and performance of the audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the parent company only financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Lin, Yung-Chih

Independent Accountants

Liu, Tzu-Meng

PricewaterhouseCoopers, Taiwan
Republic of China
March 18, 2021

---

The accompanying parent company only financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying parent company only financial statements and report of independent accountants are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.
As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

SCINOPHARM TAIWAN, LTD.
PARENT COMPANY ONLY BALANCE SHEETS
DECEMBER 31, 2020 AND 2019
(Expressed in thousands of New Taiwan dollars)

| | Assets | Notes | December 31, 2020 AMOUNT | % | December 31, 2019 AMOUNT | % |
|---|---|---|---|---|---|---|
| | **Current assets** | | | | | |
| 1100 | Cash and cash equivalents | 6(1) | $ 3,879,691 | 33 | $ 3,020,410 | 26 |
| 1110 | Financial assets at fair value through profit or loss - current | 6(2) | - | - | 2,920 | - |
| 1170 | Accounts receivable, net | 6(3) and 12 | 379,411 | 3 | 562,856 | 5 |
| 1200 | Other receivables | | 17,569 | - | 10,118 | - |
| 1210 | Other receivables - related parties | 7 | 6,348 | - | 5,697 | - |
| 1220 | Current income tax assets | 6(25) | 8,969 | - | 8,969 | - |
| 130X | Inventories | 5 and 6(4) | 1,134,947 | 10 | 1,100,695 | 10 |
| 1410 | Prepayments | | 96,841 | 1 | 107,502 | 1 |
| 11XX | **Total current assets** | | 5,523,776 | 47 | 4,819,167 | 42 |
| | **Non-current assets** | | | | | |
| 1517 | Financial assets at fair value through other comprehensive income - non-current | 6(5) | 308,115 | 3 | 415,210 | 4 |
| 1550 | Investments accounted for using equity method | 6(6) | 1,681,095 | 14 | 1,763,209 | 16 |
| 1600 | Property, plant and equipment | 6(7)(9) | 3,053,564 | 26 | 3,192,172 | 28 |
| 1755 | Right-of-use assets | 6(8) | 559,847 | 5 | 602,221 | 5 |
| 1780 | Intangible assets | | 6,885 | - | 9,458 | - |
| 1840 | Deferred income tax assets | 6(25) | 505,018 | 4 | 504,946 | 4 |
| 1915 | Prepayments for equipment | | 108,322 | 1 | 80,441 | 1 |
| 1920 | Guarantee deposits paid | | 1,029 | - | 5,244 | - |
| 1980 | Other financial assets - non-current | 8 | 29,270 | - | 29,270 | - |
| 15XX | **Total non-current assets** | | 6,253,145 | 53 | 6,602,171 | 58 |
| 1XXX | **Total assets** | | $ 11,776,921 | 100 | $ 11,421,338 | 100 |

(Continued)

SCINOPHARM TAIWAN, LTD.
PARENT COMPANY ONLY BALANCE SHEETS
DECEMBER 31, 2020 AND 2019
(Expressed in thousands of New Taiwan dollars)

| | Liabilities and Equity | Notes | December 31, 2020 AMOUNT | % | December 31, 2019 AMOUNT | % |
|---|---|---|---|---|---|---|
| | **Current liabilities** | | | | | |
| 2100 | Short-term borrowings | 6(10) | $ 9,494 | - | $ - | - |
| 2120 | Current financial liabilities at fair value through profit or loss - current | 6(2) | 2,172 | - | - | - |
| 2130 | Contract liabilities - current | 6(18) | 47,518 | - | 46,789 | - |
| 2150 | Notes payable | | 1,173 | - | 1,353 | - |
| 2170 | Accounts payable | | 126,820 | 1 | 93,643 | 1 |
| 2180 | Accounts payable - related parties | 7 | 36,598 | - | 45,517 | - |
| 2200 | Other payables | 6(11) | 308,560 | 3 | 285,292 | 3 |
| 2230 | Current income tax liabilities | 6(25) | 67,969 | 1 | - | - |
| 2280 | Lease liabilities - current | | 16,500 | - | 16,014 | - |
| 21XX | **Total current liabilities** | | 616,804 | 5 | 488,608 | 4 |
| | **Non-current liabilities** | | | | | |
| 2570 | Deferred income tax liabilities | 6(25) | - | - | 584 | - |
| 2580 | Lease liabilities - non-current | | 550,182 | 5 | 590,020 | 5 |
| 2640 | Net defined benefit liabilities | 6(12) | 79,232 | 1 | 82,182 | 1 |
| 2645 | Guarantee deposits received | | 1,300 | - | - | - |
| 25XX | **Total non-current liabilities** | | 630,714 | 6 | 672,786 | 6 |
| 2XXX | **Total liabilities** | | 1,247,518 | 11 | 1,161,394 | 10 |
| | **Equity** | | | | | |
| | Share capital | | | | | |
| 3110 | Common stock | 6(13) | 7,907,392 | 67 | 7,907,392 | 69 |
| 3200 | Capital surplus | 6(14)(15) | 1,294,689 | 11 | 1,294,605 | 12 |
| | Retained earnings | 6(5)(16) | | | | |
| 3310 | Legal reserve | | 634,265 | 5 | 612,600 | 6 |
| 3320 | Special reserve | | 67,825 | 1 | 22,829 | - |
| 3350 | Unappropriated earnings | | 658,275 | 6 | 490,344 | 4 |
| 3400 | Other equity interest | 6(6)(17) | ( 33,043) | ( 1) | ( 67,826) | ( 1) |
| 3XXX | **Total equity** | | 10,529,403 | 89 | 10,259,944 | 90 |
| | Significant contingent liabilities and unrecognised contract commitments | 7 and 9 | | | | |
| 3X2X | **Total liabilities and equity** | | $ 11,776,921 | 100 | $ 11,421,338 | 100 |

The accompanying notes are an integral part of these parent company only financial statements.

SCINOPHARM TAIWAN, LTD.
PARENT COMPANY ONLY STATEMENTS OF COMPREHENSIVE INCOME
YEARS ENDED DECEMBER 31, 2020 AND 2019
(Expressed in thousands of New Taiwan dollars, except earnings per share amounts)

| | | | Year ended December 31 | | | |
|---|---|---|---|---|---|---|
| | | | 2020 | | 2019 | |
| | Items | Notes | AMOUNT | % | AMOUNT | % |
| 4000 | Operating revenue | 6(18) and 7 | $ 3,046,220 | 100 | $ 2,813,047 | 100 |
| 5000 | Operating costs | 6(4)(12)(23)(24) and 7 | ( 1,758,472) | ( 58) | ( 1,677,387) | ( 59) |
| 5900 | Net operating margin | | 1,287,748 | 42 | 1,135,660 | 41 |
| | Operating expenses | 6(12)(23)(24), 7 and 12 | | | | |
| 6100 | Selling expenses | | ( 175,267) | ( 5) | ( 160,552) | ( 6) |
| 6200 | General and administrative expenses | | ( 455,460) | ( 15) | ( 446,039) | ( 16) |
| 6300 | Research and development expenses | | ( 206,364) | ( 7) | ( 206,570) | ( 7) |
| 6450 | (Gain on reversal of) expected credit losses | | 197 | - | ( 202) | - |
| 6000 | Total operating expenses | | ( 836,894) | ( 27) | ( 813,363) | ( 29) |
| 6900 | Operating profit | | 450,854 | 15 | 322,297 | 12 |
| | Non-operating income and expenses | | | | | |
| 7100 | Interest income | 6(19) | 21,043 | - | 28,541 | 1 |
| 7010 | Other income | 6(20) and 7 | 29,164 | 1 | 66,295 | 2 |
| 7020 | Other gains and losses | 6(2)(9)(21) and 12 | ( 36,487) | ( 1) | ( 44,362) | ( 2) |
| 7050 | Finance costs | 6(8)(22) | ( 7,072) | - | ( 8,532) | - |
| 7070 | Share of loss of associates and joint ventures accounted for using equity method | 6(6) | ( 104,620) | ( 4) | ( 117,725) | ( 4) |
| 7000 | Total non-operating income and expenses | | ( 97,972) | ( 4) | ( 75,783) | ( 3) |
| 7900 | **Profit before income tax** | | 352,882 | 11 | 246,514 | 9 |
| 7950 | Income tax expense | 6(25) | ( 70,815) | ( 2) | ( 29,858) | ( 1) |
| 8200 | **Profit for the year** | | $ 282,067 | 9 | $ 216,656 | 8 |
| | **Other comprehensive income (loss)** | | | | | |
| | **Components of other comprehensive income (loss) that will not be reclassified to profit or loss** | | | | | |
| 8311 | Actuarial losses on defined benefit plans | 6(12) | $ 2,369 | - | ($ 5,936) | - |
| 8316 | Unrealised losses from equity instruments measured at fair value through other comprehensive income | 6(5)(17) | 176,406 | 6 | ( 48,718) | ( 2) |
| 8349 | Income tax related to components of other comprehensive income that will not be reclassified to profit or loss | 6(25) | ( 473) | - | 1,187 | - |
| | **Components of other comprehensive loss that will be reclassified to profit or loss** | | | | | |
| 8361 | Financial statements translation differences of foreign operations | 6(6)(17) | 22,506 | 1 | ( 56,865) | ( 2) |
| 8300 | **Total other comprehensive loss for the year** | | $ 200,808 | 7 | ($ 110,332) | ( 4) |
| 8500 | **Total comprehensive income for the year** | | $ 482,875 | 16 | $ 106,324 | 4 |
| | Earnings per share (in dollars) | 6(26) | | | | |
| 9750 | Basic | | $ | 0.36 | $ | 0.27 |
| 9850 | Diluted | | $ | 0.36 | $ | 0.27 |

The accompanying notes are an integral part of these parent company only financial statements.

SCINOPHARM TAIWAN, LTD.
PARENT COMPANY ONLY STATEMENTS OF CHANGES IN EQUITY
YEARS ENDED DECEMBER 31, 2020 AND 2019
(Expressed in thousands of New Taiwan dollars)

| | | | | Retained Earnings | | | Other equity interest | | |
|---|---|---|---|---|---|---|---|---|---|
| | Notes | Share capital - common stock | Capital reserve | Legal reserve | Special reserve | Unappropriated earnings | Financial statements translation differences of foreign operations | Unrealised gains (losses) from financial assets measured at fair value through other comprehensive income | Amount |
| For the year ended December 31, 2019 | | | | | | | | | |
| Balance at January 1, 2019 | | $ 7,907,392 | $ 1,292,555 | $ 568,302 | $ 22,829 | $ 708,338 | ($ 41,252) | $ 80,868 | $ 10,539,032 |
| Net income for the year | | - | - | - | - | 216,656 | - | - | 216,656 |
| Other comprehensive loss for the year | 6(5)(6)(17) | - | - | - | - | (4,749) | (56,865) | (48,718) | (110,332) |
| Total comprehensive income (loss) for the year | | - | - | - | - | 211,907 | (56,865) | (48,718) | 106,324 |
| Distribution of 2018 net income: | | | | | | | | | |
| Legal reserve | | - | - | 44,298 | - | (44,298) | - | - | - |
| Cash dividends | 6(16) | - | - | - | - | (387,462) | - | - | (387,462) |
| Employee stock option compensation cost | 6(14)(15) | - | 2,050 | - | - | - | - | - | 2,050 |
| Disposal of equity instruments at fair value through other comprehensive income | 6(5)(17) | - | - | - | - | 1,859 | - | (1,859) | - |
| Balance at December 31, 2019 | | $ 7,907,392 | $ 1,294,605 | $ 612,600 | $ 22,829 | $ 490,344 | ($ 98,117) | $ 30,291 | $ 10,259,944 |
| For the year ended December 31, 2020 | | | | | | | | | |
| Balance at January 1, 2020 | | $ 7,907,392 | $ 1,294,605 | $ 612,600 | $ 22,829 | $ 490,344 | ($ 98,117) | $ 30,291 | $ 10,259,944 |
| Net income for the year | | - | - | - | - | 282,067 | - | - | 282,067 |
| Other comprehensive income for the year | 6(5)(6)(17) | - | - | - | - | 1,896 | 22,506 | 176,406 | 200,808 |
| Total comprehensive income | | - | - | - | - | 283,963 | 22,506 | 176,406 | 482,875 |
| Distribution of 2019 net income: | | | | | | | | | |
| Legal reserve | | - | - | 21,665 | - | (21,665) | - | - | - |
| Special reserve | | - | - | - | 44,996 | (44,996) | - | - | - |
| Cash dividends | 6(16) | - | - | - | - | (213,500) | - | - | (213,500) |
| Employee stock option compensation cost | 6(14)(15) | - | 84 | - | - | - | - | - | 84 |
| Disposal of equity instruments at fair value through other comprehensive income | 6(5)(17) | - | - | - | - | 164,129 | - | (164,129) | - |
| Balance at December 31, 2020 | | $ 7,907,392 | $ 1,294,689 | $ 634,265 | $ 67,825 | $ 658,275 | ($ 75,611) | $ 42,568 | $ 10,529,403 |

The accompanying notes are an integral part of these parent company only financial statements.

SCINOPHARM TAIWAN, LTD.
PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2020 AND 2019
(Expressed in thousands of New Taiwan dollars)

| | Notes | Year ended December 31 2020 | Year ended December 31 2019 |
|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | | | |
| Profit before tax | | $ 352,882 | $ 246,514 |
| Adjustments | | | |
| Adjustments to reconcile profit (loss) | | | |
| Loss (gain) on valuation of financial assets and liabilities at fair value through profit or loss | | 5,092 | ( 2,511 ) |
| (Gain on reversal of) expected credit losses | 12 | ( 197 ) | 202 |
| Reversal of allowance for loss on inventory market price decline | 6(4) | ( 74,623 ) | ( 2,590 ) |
| Provision for obsolescence of supplies | | 3,312 | 5,972 |
| Share of loss of subsidiaries, associates and joint ventures accounted for using equity method | 6(6) | 104,620 | 117,725 |
| Depreciation of property, plant and equipment | 6(7)(23) | 266,984 | 272,707 |
| Depreciation of right-of-use assets | 6(8)(23) | 12,794 | 15,148 |
| Property, plant and equipment transferred to loss | 6(7)(21) | 11,900 | 22,726 |
| Gain on disposal of property, plant and equipment | 6(21) | 2,587 | - |
| (Gain on reversal of) impairment loss | 6(7)(9)(21) | ( 4,253 ) | 707 |
| Amortisation | 6(23) | 6,044 | 7,693 |
| Prepayments for equipment transferred to loss | | - | 1,967 |
| Employee stock option compensation cost | 6(14)(15) | 84 | 2,050 |
| Interest income | 6(19) | ( 21,043 ) | ( 28,541 ) |
| Interest expense | 6(22) | 7,072 | 8,532 |
| Changes in operating assets and liabilities | | | |
| Changes in operating assets | | | |
| Accounts receivable | | 183,642 | ( 12,318 ) |
| Other receivables | | ( 6,147 ) | 5,481 |
| Other receivables - related parties | | ( 651 ) | ( 72 ) |
| Inventories | | 40,371 | 145,483 |
| Prepayments | | 7,349 | ( 33,201 ) |
| Changes in operating liabilities | | | |
| Contract liabilities - current | | 729 | 24,248 |
| Notes payable | | ( 180 ) | 205 |
| Accounts payable | | 33,177 | 19,904 |
| Accounts payable - related parties | | ( 8,919 ) | 6,210 |
| Other payables | | 11,456 | ( 16,561 ) |
| Net defined benefit liabilities - non-current | | ( 581 ) | ( 617 ) |
| Cash inflow generated from operations | | 933,501 | 807,063 |
| Interest received | | 19,739 | 28,599 |
| Interest paid | | ( 7,072 ) | ( 9,410 ) |
| Income tax paid | | ( 3,975 ) | ( 136,614 ) |
| Net cash flows from operating activities | | 942,193 | 689,638 |

(Continued)

SCINOPHARM TAIWAN, LTD.
PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2020 AND 2019
(Expressed in thousands of New Taiwan dollars)

| | | Year ended December 31 | |
|---|---|---|---|
| | Notes | 2020 | 2019 |
| CASH FLOWS FROM INVESTING ACTIVITIES | | | |
| Proceeds from disposal of financial assets at fair value through other comprehensive income | 6(5) | $ 283,501 | $ 4,189 |
| Acquisition of investments accounted for using equity method - subsidiary | 6(6) | - | ( 1,192,251 ) |
| Cash paid for acquisition of property, plant and equipment | 6(27) | ( 64,529 ) | ( 15,925 ) |
| Proceeds from disposal of property, plant and equipment | | 124 | - |
| Acquisition of intangible assets | | ( 2,310 ) | ( 2,249 ) |
| Increase in prepayments for equipment | | ( 91,435 ) | ( 71,998 ) |
| Decrease (increase) in guarantee deposits paid | | 4,215 | ( 4,341 ) |
| Net cash flows from (used in) investing activities | | 129,566 | ( 1,282,575 ) |
| CASH FLOWS FROM FINANCING ACTIVITIES | | | |
| Increase (decrease) in short-term borrowings | 6(28) | 9,494 | ( 61,694 ) |
| Repayment of the principal portion of lease liabilities | 6(28) | ( 9,772 ) | ( 11,335 ) |
| Increase (decrease) in guarantee deposits received | 6(28) | 1,300 | ( 1,618 ) |
| Payment of cash dividends | 6(16) | ( 213,500 ) | ( 387,462 ) |
| Net cash flows used in financing activities | | ( 212,478 ) | ( 462,109 ) |
| Net increase (decrease) in cash and cash equivalents | | 859,281 | ( 1,055,046 ) |
| Cash and cash equivalents at beginning of year | 6(1) | 3,020,410 | 4,075,456 |
| Cash and cash equivalents at end of year | 6(1) | $ 3,879,691 | $ 3,020,410 |

The accompanying notes are an integral part of these parent company only financial statements.

**Appendix 5**

INDEPENDENT AUDITORS' REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of ScinoPharm Taiwan, Ltd.

## *Opinion*

We have audited the accompanying consolidated balance sheets of ScinoPharm Taiwan, Ltd. and subsidiaries (the "Group") as at December 31, 2020 and 2019, and the related consolidated statements of comprehensive income, of changes in equity and of cash flows for the years then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as at December 31, 2020 and 2019, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations as endorsed by the Financial Supervisory Commission.

## *Basis for opinion*

We conducted our audits in accordance with the Regulations Governing Auditing and Attestation of Financial Statements by Certified Public Accountants and generally accepted auditing standards in the Republic of China. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the consolidated financial statements section of our report. We are independent of the Group in accordance with the Norm of Professional Ethics for Certified Public Accountants of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## *Key audit matters*

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Group's 2020 consolidated financial statements. These matters were addressed in the context of our audit of the consolidated financial statements as a whole and, in forming our opinion thereon, we do not provide a separate opinion on these matters.

The key audit matters for the Group's 2020 consolidated financial statements are stated as follows:

## *Cutoff of export revenue from Taiwan*

Description

Refer to Note 4(28) for accounting policies on revenue recognition and Note 6(19) for accounting items on operating revenue.

The Group's sales revenue mainly arise from the manufacture and sales of Active Pharmaceutical Ingredient ("API"), which primarily consists of export sales. The Group recognises export sales revenue based on the terms and conditions of transactions which vary with different customers. As revenue recognition involves manual processes and is material to the financial statements, we consider the cutoff of export revenue from Taiwan a key audit matter.

How our audit addressed the matter

We performed the following key audit procedures in response to the above key audit matter:

1. Understood and assessed the effectiveness of internal controls over cutoff of sales revenue and tested the effectiveness of internal controls over shipping and billing.
2. Checked the completeness of the export sales details for a certain period around balance sheet date and performed cutoff tests on a random basis, which included checking the terms and conditions of transactions, verifying against supporting documents, and checking whether inventory movements and costs of sales were recognised in the appropriate period.

## *Inventory valuation*

Description

Refer to Note 4(13) for accounting policies on inventory valuation, Note 5(2)1 for the uncertainty of accounting estimates and assumptions applied on inventory valuation, and Note 6(5) for details of inventories. As at December 31, 2020, the balances of inventory and allowance for inventory valuation losses were $1,643,409 thousand and $397,539 thousand, respectively.

The Group is primarily engaged in the manufacture and sales of API. As the manufacturing process is relatively complicated and time-consuming, materials require longer lead time, the waiting period for product registration is long, and the timing of the product launch may be deferred, there is higher risk of incurring loss on inventory valuation. For inventories sold under normal terms, the Group measures inventories at the lower of cost and net realisable value. For inventories aging over a certain period of time and are individually identified as obsolete inventories, the net realisable value is calculated based on the historical information of inventory turnover. Since the calculation of net realisable value involves subjective judgement and the ending balance of inventory is material to the financial statements, we consider the valuation of inventory a key audit matter.

How our audit addressed the matter

We performed the following key audit procedures in response to the above key audit matter:

1. Evaluated the reasonableness of provision policies and procedures on allowance for inventory valuation losses, including the historical data of inventory turnover and judgement of obsolete inventory.
2. Verified whether the dates used in the inventory aging reports that the Group applied to value inventories were accurate. Recalculated and evaluated the reasonableness of allowance for inventory valuation losses in order to confirm whether the reported information was in line with the Group’s policies.
3. Selected samples from inventory items by each sequence number to verify its realisable value and to evaluate the reasonableness of allowance for inventory valuation loss.

## *Other matter – Parent company only financial reports*

We have audited and expressed an unqualified opinion on the parent company only financial statements of ScinoPharm Taiwan, Ltd. as at and for the years ended December 31, 2020 and 2019.

## *Responsibilities of management and those charged with governance for the consolidated financial statements*

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations as endorsed by the Financial Supervisory Commission, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including audit committee, are responsible for overseeing the Group's financial reporting process.

### *Auditors' responsibilities for the audit of the consolidated financial statements*

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the generally accepted auditing standards in the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with the generally accepted auditing standards in the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.

3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Lin, Yung-Chih

Independent Accountants

Liu, Tzu-Meng

PricewaterhouseCoopers, Taiwan
Republic of China
March 18, 2021

---

The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and report of independent accountants are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.
As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2020 AND 2019
(Expressed in thousands of New Taiwan dollars)

| | Assets | Notes | December 31, 2020 AMOUNT | % | December 31, 2019 AMOUNT | % |
|---|---|---|---|---|---|---|
| | **Current assets** | | | | | |
| 1100 | Cash and cash equivalents | 6(1) | $ 4,054,948 | 34 | $ 3,304,978 | 28 |
| 1110 | Financial assets at fair value through profit or loss - current | 6(2) | - | - | 2,920 | - |
| 1136 | Financial assets at amortised cost - current | 6(3) | - | - | 172,220 | 1 |
| 1170 | Accounts receivable, net | 6(4) and 12 | 386,508 | 3 | 590,336 | 5 |
| 1200 | Other receivables | | 77,456 | 1 | 71,149 | 1 |
| 1220 | Current income tax assets | 6(26) | 8,969 | - | 8,968 | - |
| 130X | Inventories | 5 and 6(5) | 1,245,870 | 11 | 1,124,332 | 10 |
| 1410 | Prepayments | | 108,075 | 1 | 131,681 | 1 |
| 1476 | Other financial assets - current | 8 and 9 | 34,311 | - | - | - |
| 11XX | **Total current assets** | | 5,916,137 | 50 | 5,406,584 | 46 |
| | **Non-current assets** | | | | | |
| 1517 | Financial assets at fair value through other comprehensive income - non-current | 6(6) | 308,115 | 3 | 415,210 | 4 |
| 1600 | Property, plant and equipment | 6(7)(9) | 4,210,746 | 36 | 4,433,860 | 38 |
| 1755 | Right-of-use assets | 6(8) | 629,886 | 5 | 673,087 | 6 |
| 1780 | Intangible assets | | 8,900 | - | 14,068 | - |
| 1840 | Deferred income tax assets | 5 and 6(26) | 602,979 | 5 | 606,123 | 5 |
| 1915 | Prepayments for equipment | | 133,960 | 1 | 85,361 | 1 |
| 1920 | Guarantee deposits paid | | 6,770 | - | 11,001 | - |
| 1980 | Other financial assets - non-current | 8 | 29,270 | - | 29,270 | - |
| 15XX | **Total non-current assets** | | 5,930,626 | 50 | 6,267,980 | 54 |
| 1XXX | **Total assets** | | $ 11,846,763 | 100 | $ 11,674,564 | 100 |

(Continued)

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2020 AND 2019
(Expressed in thousands of New Taiwan dollars)

| | Liabilities and Equity | Notes | December 31, 2020 AMOUNT | % | December 31, 2019 AMOUNT | % |
|---|---|---|---|---|---|---|
| | **Current liabilities** | | | | | |
| 2100 | Short-term borrowings | 6(10) | $ 9,494 | - | $ 89,766 | 1 |
| 2120 | Financial liabilities at fair value through profit or loss - current | 6(2) | 2,172 | - | - | - |
| 2130 | Contract liabilities - current | 6(19) | 66,846 | 1 | 55,985 | - |
| 2150 | Notes payable | | 1,173 | - | 1,353 | - |
| 2170 | Accounts payable | | 159,671 | 1 | 101,018 | 1 |
| 2200 | Other payables | 6(11) | 362,821 | 3 | 333,376 | 3 |
| 2230 | Current income tax liabilities | 6(26) | 67,969 | 1 | 1 | - |
| 2280 | Lease liabilities - current | | 16,500 | - | 16,014 | - |
| 2320 | Long-term liabilities, current portion | 6(12) and 9 | - | - | 144,234 | 1 |
| 21XX | **Total current liabilities** | | 686,646 | 6 | 741,747 | 6 |
| | **Non-current liabilities** | | | | | |
| 2570 | Deferred income tax liabilities | 6(26) | - | - | 584 | - |
| 2580 | Lease liabilities - non-current | | 550,182 | 4 | 590,020 | 5 |
| 2640 | Net defined benefit liabilities | 6(13) | 79,232 | 1 | 82,182 | 1 |
| 2645 | Guarantee deposits received | | 1,300 | - | 87 | - |
| 25XX | **Total non-current liabilities** | | 630,714 | 5 | 672,873 | 6 |
| 2XXX | **Total liabilities** | | 1,317,360 | 11 | 1,414,620 | 12 |
| | **Equity attributable to owners of parent** | | | | | |
| | Share capital | | | | | |
| 3110 | Common stock | 6(14) | 7,907,392 | 67 | 7,907,392 | 68 |
| 3200 | Capital surplus | 6(15)(16) | 1,294,689 | 11 | 1,294,605 | 12 |
| | Retained earnings | 6(17) | | | | |
| 3310 | Legal reserve | | 634,265 | 5 | 612,600 | 5 |
| 3320 | Special reserve | | 67,825 | 1 | 22,829 | - |
| 3350 | Unappropriated earnings | | 658,275 | 6 | 490,344 | 4 |
| 3400 | Other equity interest | 6(18) | ( 33,043) | ( 1) | ( 67,826) | ( 1) |
| 3XXX | **Total equity** | | 10,529,403 | 89 | 10,259,944 | 88 |
| | Significant contingent liabilities and unrecognised contract commitments | 9 | | | | |
| 3X2X | **Total liabilities and equity** | | $ 11,846,763 | 100 | $ 11,674,564 | 100 |

The accompanying notes are an integral part of these consolidated financial statements.

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
YEARS ENDED DECEMBER 31, 2020 AND 2019
(Expressed in thousands of New Taiwan dollars, except earnings per share amounts)

| | Items | Notes | Year ended December 31 2020 AMOUNT | 2020 % | 2019 AMOUNT | 2019 % |
|---|---|---|---|---|---|---|
| 4000 | Operating revenue | 6(19) | $ 3,082,928 | 100 | $ 2,892,783 | 100 |
| 5000 | Operating costs | 6(5)(24)(25) | ( 1,765,469) | ( 57) | ( 1,716,378) | ( 59) |
| 5900 | Net operating margin | | 1,317,459 | 43 | 1,176,405 | 41 |
| | Operating expenses | 6(24)(25), 7 and 12 | | | | |
| 6100 | Selling expenses | | ( 170,904) | ( 6) | ( 157,168) | ( 6) |
| 6200 | General and administrative expenses | | ( 525,418) | ( 17) | ( 513,796) | ( 18) |
| 6300 | Research and development expenses | | ( 245,633) | ( 8) | ( 238,373) | ( 8) |
| 6450 | (Gain on reversal of) expected credit losses | | 219 | - | ( 214) | - |
| 6000 | Total operating expenses | | ( 941,736) | ( 31) | ( 909,551) | ( 32) |
| 6900 | Operating profit | | 375,723 | 12 | 266,854 | 9 |
| | Non-operating income and expenses | | | | | |
| 7100 | Interest income | 6(3)(20) | 27,408 | 1 | 37,976 | 1 |
| 7010 | Other income | 6(21) | 16,378 | 1 | 53,874 | 2 |
| 7020 | Other gains and losses | 6(2)(9)(22) and 12 | ( 45,838) | ( 2) | ( 37,961) | ( 1) |
| 7050 | Finance costs | 6(8)(23) | ( 15,166) | - | ( 55,689) | ( 2) |
| 7000 | Total non-operating income and expenses | | ( 17,218) | - | ( 1,800) | - |
| 7900 | **Profit before income tax** | | 358,505 | 12 | 265,054 | 9 |
| 7950 | Income tax expense | 6(26) | ( 76,438) | ( 3) | ( 48,398) | ( 1) |
| 8200 | **Profit for the year** | | $ 282,067 | 9 | $ 216,656 | 8 |
| | **Other comprehensive income** | | | | | |
| | **Components of other comprehensive (loss) income that will not be reclassified to profit or loss** | | | | | |
| 8311 | Actuarial losses on defined benefit plans | 6(13) | $ 2,369 | - | ($ 5,936) | - |
| 8316 | Unrealised (losses) gains from equity instrument measured at fair value through other comprehensive income | 6(6)(18) | 176,406 | 6 | ( 48,718) | ( 2) |
| 8349 | Income tax related to components of other comprehensive income that will not be reclassified to profit or loss | 6(26) | ( 473) | - | 1,187 | - |
| | **Components of other comprehensive income (loss) that will be reclassified to profit or loss** | | | | | |
| 8361 | Financial statements translation differences of foreign operations | 6(18) | 22,506 | 1 | ( 56,865) | ( 2) |
| 8300 | **Total other comprehensive income (loss) for the year** | | $ 200,808 | 7 | ($ 110,332) | ( 4) |
| 8500 | **Total comprehensive income for the year** | | $ 482,875 | 16 | $ 106,324 | 4 |
| | Profit attributable to: | | | | | |
| 8610 | Owners of the parent | | $ 282,067 | 9 | $ 216,656 | 8 |
| | Comprehensive income (loss) attributable to: | | | | | |
| 8710 | Owners of the parent | | $ 482,875 | 16 | $ 106,324 | 4 |
| | Earnings per share (in dollars) | 6(27) | | | | |
| 9750 | Basic | | $ | 0.36 | $ | 0.27 |
| 9850 | Diluted | | $ | 0.36 | $ | 0.27 |

The accompanying notes are an integral part of these consolidated financial statements.

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
YEARS ENDED DECEMBER 31, 2020 AND 2019
(Expressed in thousands of New Taiwan dollars, except as otherwise indicated)

| | | Equity attributable to owners of the parent | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | | Retained Earnings | | | Other equity interest | | |
| | Notes | Share capital - common stock | Capital reserve | Legal reserve | Special reserve | Unappropriated earnings | Financial statements translation differences of foreign operations | Unrealised gains from financial assets measured at fair value through other comprehensive income | Total equity |
| For the year ended December 31, 2019 | | | | | | | | | |
| Balance at January 1, 2019 | | $ 7,907,392 | $ 1,292,555 | $ 568,302 | $ 22,829 | $ 708,338 | ($ 41,252 ) | $ 80,868 | $ 10,539,032 |
| Net income for the year ended December 31, 2019 | | - | - | - | - | 216,656 | - | - | 216,656 |
| Other comprehensive loss for the year ended December 31, 2019 | 6(6)(18) | - | - | - | - | ( 4,749 ) | ( 56,865 ) | ( 48,718 ) | ( 110,332 ) |
| Total comprehensive income (loss) for the year ended December 31, 2019 | | - | - | - | - | 211,907 | ( 56,865 ) | ( 48,718 ) | 106,324 |
| Distribution of 2018 net income: | | | | | | | | | |
| Legal reserve | | - | - | 44,298 | - | ( 44,298 ) | - | - | - |
| Cash dividends | 6(17) | - | - | - | - | ( 387,462 ) | - | - | ( 387,462 ) |
| Employee stock option compensation cost | 6(15)(16) | - | 2,050 | - | - | - | - | - | 2,050 |
| Disposal of equity instruments at fair value through other comprehensive income | 6(6)(18) | - | - | - | - | 1,859 | - | ( 1,859 ) | - |
| Balance at December 31, 2019 | | $ 7,907,392 | $ 1,294,605 | $ 612,600 | $ 22,829 | $ 490,344 | ($ 98,117 ) | $ 30,291 | $ 10,259,944 |
| For the year ended December 31, 2020 | | | | | | | | | |
| Balance at January 1, 2020 | | $ 7,907,392 | $ 1,294,605 | $ 612,600 | $ 22,829 | $ 490,344 | ($ 98,117 ) | $ 30,291 | $ 10,259,944 |
| Net income for the year ended December 31, 2020 | | - | - | - | - | 282,067 | - | - | 282,067 |
| Other comprehensive income for the year ended December 31, 2020 | 6(6)(18) | - | - | - | - | 1,896 | 22,506 | 176,406 | 200,808 |
| Total comprehensive income for the year ended December 31, 2020 | | - | - | - | - | 283,963 | 22,506 | 176,406 | 482,875 |
| Distribution of 2019 net income: | | | | | | | | | |
| Legal reserve | | - | - | 21,665 | - | ( 21,665 ) | - | - | - |
| Special reserve | | - | - | - | 44,996 | ( 44,996 ) | - | - | - |
| Cash dividends | 6(17) | - | - | - | - | ( 213,500 ) | - | - | ( 213,500 ) |
| Employee stock option compensation cost | 6(15)(16) | - | 84 | - | - | - | - | - | 84 |
| Disposal of equity instruments at fair value through other comprehensive income | 6(6)(18) | - | - | - | - | 164,129 | - | ( 164,129 ) | - |
| Balance at December 31, 2020 | | $ 7,907,392 | $ 1,294,689 | $ 634,265 | $ 67,825 | $ 658,275 | ($ 75,611 ) | $ 42,568 | $ 10,529,403 |

The accompanying notes are an integral part of these consolidated financial statements.

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2020 AND 2019
(Expressed in thousands of New Taiwan dollars)

| | Notes | Year ended December 31 2020 | 2019 |
|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | | | |
| Profit before tax | | $ 358,505 | $ 265,054 |
| Adjustments | | | |
| Adjustments to reconcile profit (loss) | | | |
| Loss (gain) on valuation of financial assets and liabilities at fair value through profit or loss | | 5,092 | ( 2,511 ) |
| (Gain on reversal of) expected credit losses | 12 | ( 219 ) | 214 |
| Reversal of allowance for inventory market price decline | 6(5) | ( 74,840 ) | ( 51,413 ) |
| Provision for obsolescence of supplies | | 3,958 | 8,006 |
| Depreciation of property, plant and equipment | 6(7)(24) | 369,189 | 379,537 |
| Depreciation of right-of-use assets | 6(8)(24) | 14,539 | 16,972 |
| Property, plant and equipment transferred to loss | 6(7)(22) | 11,900 | 22,726 |
| Loss on disposal of property, plant and equipment | 6(22) | 3,157 | 39 |
| (Gain on reversal of) impairment loss | 6(7)(9)(22) | ( 4,282 ) | 707 |
| Amortisation | 6(24) | 9,469 | 12,206 |
| Prepayments for equipment transferred to loss | | - | 1,967 |
| Employee stock option compensation cost | 6(15)(16) | 84 | 2,050 |
| Interest income | 6(20) | ( 27,408 ) | ( 37,976 ) |
| Interest expense | 6(23) | 15,166 | 55,689 |
| Changes in operating assets and liabilities | | | |
| Changes in operating assets | | | |
| Accounts receivable | | 204,047 | ( 31,599 ) |
| Other receivables | | ( 8,266 ) | 33,791 |
| Inventories | | ( 47,959 ) | 293,845 |
| Prepayments | | 19,724 | ( 43,565 ) |
| Changes in operating liabilities | | | |
| Contract liabilities - current | | 10,861 | 25,368 |
| Notes payable | | ( 180 ) | 205 |
| Accounts payable | | 58,653 | 11,625 |
| Other payables | | 18,047 | ( 12,793 ) |
| Net defined benefit liabilities - non-current | | ( 581 ) | ( 617 ) |
| Cash inflow generated from operations | | 938,656 | 949,527 |
| Interest received | | 29,367 | 37,057 |
| Interest paid | | ( 15,327 ) | ( 63,570 ) |
| Income tax paid | | ( 6,384 ) | ( 134,069 ) |
| Net cash flows from operating activities | | 946,312 | 788,945 |

(Continued)

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2020 AND 2019
(Expressed in thousands of New Taiwan dollars)

| | Notes | Year ended December 31 2020 | 2019 |
|---|---|---|---|
| CASH FLOWS FROM INVESTING ACTIVITIES | | | |
| Increase in financial assets at amortised cost - current | | ($ 607,970 ) | ($ 710,890 ) |
| Proceeds from disposal of financial assets at amortised cost - current | | 779,230 | 717,940 |
| Increase in other financial assets - current | | ( 34,311 ) | - |
| Proceeds from disposal of financial assets at fair value through other comprehensive income | 6(6) | 283,501 | 4,189 |
| Cash paid for acquisition of property, plant and equipment | 6(28) | ( 65,236 ) | ( 21,351 ) |
| Proceeds from disposal of property, plant and equipment | | 135 | 188 |
| Acquisition of intangible assets | | ( 3,128 ) | ( 3,185 ) |
| Increase in prepayments for equipment | | ( 114,732 ) | ( 81,164 ) |
| Decrease (increase) in guarantee deposits paid | | 4,231 | ( 4,116 ) |
| Net cash flows from (used in) investing activities | | 241,720 | ( 98,389 ) |
| CASH FLOWS FROM FINANCING ACTIVITIES | | | |
| Decrease in short-term borrowings | 6(29) | ( 79,420 ) | ( 140,356 ) |
| Repayment of the principal portion of lease liabilities | 6(29) | ( 9,772 ) | ( 11,335 ) |
| Increase in long-term borrowings | 6(29) | 89,265 | 185,704 |
| Decrease in long-term borrowings | 6(29) | ( 232,695 ) | ( 1,216,792 ) |
| Increase (decrease) in guarantee deposits received | 6(29) | 1,214 | ( 1,618 ) |
| Payment of cash dividents | 6(17) | ( 213,500 ) | ( 387,462 ) |
| Net cash flows used in financing activities | | ( 444,908 ) | ( 1,571,859 ) |
| Effect of foreign exchange rate changes | | 6,846 | ( 17,057 ) |
| Net increase (decrease) in cash and cash equivalents | | 749,970 | ( 898,360 ) |
| Cash and cash equivalents at beginning of year | 6(1) | 3,304,978 | 4,203,338 |
| Cash and cash equivalents at end of year | 6(1) | $ 4,054,948 | $ 3,304,978 |

The accompanying notes are an integral part of these consolidated financial statements.

**Appendix 6**

## ScinoPharm Taiwan, Ltd.
## Earnings Distribution Plan for Fiscal Year 2020

| Item | Amount (TWD) |
|---|---|
| After-tax net profit earned in 2020 | $ 282,067,288 |
| Plus: Actuarial gain(loss) presented in retained earnings | 1,895,265 |
| Plus: Disposal of equity instruments at fair value through other comprehensive income | 164,129,027 |
| Less: Legal reserve | (44,809,158) |
| Plus: Reversal of special reserve | 34,782,774 |
| Distributable profit from this period | 438,065,196 |
| Plus: Accumulated undistributed earnings from previous period | 210,183,065 |
| Total distributable earnings as of this period | 648,248,261 |
| Dividends to shareholders (Cash dividend TWD 500 on each 1,000 shares held) | (395,369,611) |
| Undistributed earnings as of the end of the period | $ 252,878,650 |

Notes:

1. In terms of earnings distribution for fiscal year 2020, priority is given to distributing the earnings posted in the given fiscal year while retained earnings from the previous fiscal year is drawn on to make up for any deficiency.
2. The actual amount of cash dividend paid to the shareholders shall be paid up to the rounded number with the fraction (if any) to be accounted as Other Income of the Company

Chairperson：Chih-Hsien Lo CEO：Tsung-Ming Su Chief Accountant：Chih-Hui Lin

**Appendix 7**

## ScinoPharm Taiwan, Ltd.
## Proposed Amendments to the Rules of Procedures for Shareholders' Meeting

| Current Provision | Revision Provision | Remark |
|---|---|---|
| **Article 8**<br>(Item 1. Omitted)<br>The chairperson of the meeting shall announce to commence the meeting in due course, which announcement may be postponed twice and only twice and up to not more than an hour in total pending the fulfillment of representation of the majority of the total issued shares of the Company.<br>If the total shares represented at the meeting still account for less than one third (1/3) of the total issued shares of the Company after the chairperson has duly twice postponed commencing the meeting, the chairperson shall announce the call for the meeting unsuccessful.<br>Where the total shares represented at the meeting not amounting to the quorum attains one third (1/3) or more of the total issued shares of the Company after the commencement of the meeting is duly twice postponed in accordance with the preceding paragraph, tentative resolutions may be adopted by the meeting under paragraph one of Article 175 of the Company Act, which tentative resolutions must be notified to the shareholders each with the notice of a re-scheduled Shareholders' Meeting to be held within a month.<br>If the quorum of due representation of the majority of the total issued shares of the Company is fulfilled before the meeting ends, the chairperson shall submit the tentative resolutions adopted (if any) to the meeting for re-voting and adoption by the meeting pursuant to Article 174 of the Company Act. | **Article 8**<br>(Item 1. Omitted)<br>The chairperson of the meeting shall announce to commence the meeting in due course <u>and publicize information on both the number of shares without voting right and number of shares in attendance. The</u> announcement may be postponed twice and only twice and up to not more than an hour in total pending the fulfillment of representation of the majority of the total issued shares of the Company.<br>If the total shares represented at the meeting still account for less than one third (1/3) of the total issued shares of the Company after the chairperson has duly twice postponed commencing the meeting, the chairperson shall announce the call for the meeting unsuccessful.<br>Where the total shares represented at the meeting not amounting to the quorum attains one third (1/3) or more of the total issued shares of the Company after the commencement of the meeting is duly twice postponed in accordance with the preceding paragraph, tentative resolutions may be adopted by the meeting under paragraph one of Article 175 of the Company Act, which tentative resolutions must be notified to the shareholders each with the notice of a re-scheduled Shareholders' Meeting to be held within a month.<br>If the quorum of due representation of the majority of the total issued shares of the Company is fulfilled before the meeting ends, the chairperson shall submit the tentative resolutions adopted (if any) to the meeting for re-voting and adoption by the meeting pursuant to Article 174 of the Company Act. | Revised item 2, to uphold corporate governance and shareholders' interests. |

| Current Provision | Revision Provision | Remark |
|---|---|---|
| **Article 16**<br>The election (if any) of the director(s) of the Company at the shareholders meeting shall be in accordance with the relevant bylaw of the Company and the result of the election shall be announced at the meeting including the name of each director elect and the amount of votes for them each.<br>(Item 2: Omitted) | **Article 16**<br>The election (if any) of the director(s) of the Company at the shareholders meeting shall be in accordance with the relevant bylaw of the Company and the result of the election shall be announced at the meeting including the name of each director elect and the amount of votes for them each. <u>List of directors not elected and the amount of votes they obtain should also be announced.</u><br>(Item 2: Omitted) | Revised item 1, to uphold corporate governance and shareholders' interests. |
| **Article 21**<br>These Rules and all subsequent amendments shall come into force on the relevant resolution adopted by the shareholders meeting.<br>These Rules were established on March 13, 2003 and subsequently revised as follows: May 14, 2004, September 25, 2009, July 6, 2010, June 13, 2012, June 21, 2013, Jun 23, 2015 and June 30, 2020. | **Article 21**<br>These Rules and all subsequent amendments shall come into force on the relevant resolution adopted by the shareholders meeting.<br>These Rules were established on March 13, 2003 and subsequently revised as follows: May 14, 2004, September 25, 2009, July 6, 2010, June 13, 2012, June 21, 2013, Jun 23, 2015, June 30, 2020 <u>and July 21, 2021.</u> | In line with this revision, previous revision dates have been added. |

**Appendix 8**

## ScinoPharm Taiwan, Ltd.
## Information of Director Nominees

| Share holder No. | Name of Nominee | Academic Attainments | Major Past Career | Major Current Position | Amount of Shares Held (Unit: Share) [Note] |
|---|---|---|---|---|---|
| 4 | Uni-President Enterprises Corp. Representative: Chih-Hsien Lo | MBA, UCLA, USA | President of Uni-President Enterprises Corp. | Chairman of：<br>Uni-President Enterprises Corp.<br>President Chain Store Corp.<br>Ton Yi Industrial Corp<br>Prince Housing & development Corp.<br>TTET Union Corp.<br>ScinoPharm Taiwan, Ltd. | 299,968,639 |
| 4 | Uni-President Enterprises Corp. Representative: Tsung-Ming Su | MBA, Iowa State Univ., USA | Chief Financial Officer of Uni-President Enterprises Corp. | President of：<br>ScinoPharm Taiwan, Ltd.<br>Director of：<br>ScinoPharm Taiwan, Ltd. | 299,968,639 |
| 4 | Uni-President Enterprises Corp. Representative: Tsung-Pin Wu | Accounting, Chung Yuan Christian University | Supervisor of：<br>Tait Marketing & Distribution Co., Ltd. | Chief Accounting Officer of Uni-President Enterprises Corp.<br>Director of：<br>ScinoPharm Taiwan, Ltd. | 299,968,639 |
| 4 | Uni-President Enterprises Corp. Representative: Fu-Jung Lai | MBA, Kun Shan Univ., R.O.C. | Director of Uni-President Social Welfare Charity Foundation | Vice President of the President's Office of Uni-President Enterprises Corp./ Corporate Governance Officer<br>Director of：<br>ScinoPharm Taiwan, Ltd. | 299,968,639 |
| 4 | Uni-President Enterprises Corp. Representative: Chin-Yuan Cheng | Ph.D., Chemical and Biomolecular Engineering Department, The Ohio State University, U.S.A. | Director, Dairy Products Development Division, Uni-President Enterprises Corp. | Director, Purchasing Division, Uni-President Enterprises Corp | 299,968,639 |
| 4 | Uni-President Enterprises Corp. Representative: Jia-Horng Guo | Master of Finance, University of Illinois | Director of ：<br>Taishin Securities Co., Ltd | Chairman of：<br>Taishin Securities Co., Ltd<br>Director of：<br>ScinoPharm Taiwan, Ltd. | 299,968,639 |
| 5 | Tainan Spinning Co., Ltd. Representative: Po-Ming Hou | Chinese Culture University | Chairman and President of Tainan Spinning Co., Ltd | Chairman of：<br>Tainan Spinning Co., Ltd<br>Director of：<br>ScinoPharm Taiwan, Ltd. | 23,605,921 |
| 860 | Kao Chyuan Inv. Co., Ltd. Representative: Shiow-Ling Kao | Marymount College, USA. | Chairman of：<br>President Fair Development Corp. | Chairman of：<br>Kao Chyuan Inv. Co., Ltd.<br>Director of：<br>ScinoPharm Taiwan Ltd. | 14,832,733 |
| 861 | President International Development Corp. Representative: Chiou-Ru Shih | MA in Economics, University of Hawaii | Vice Director of President International Development Corp. | Vice President of President International Development Corp.<br>Director of：<br>ScinoPharm Taiwan, Ltd. | 28,673,421 |

| Share holder No. | Name of Nominee | Academic Attainments | Major Past Career | Major Current Position | Amount of Shares Held (Unit: Share) [Note] |
|---|---|---|---|---|---|
| 1 | National Development Fund, Executive Yuan Representative: Ming-Chuan Hsieh | Master of Health Services Administration, China Medical University | Executive Supervisor, Taiwan Health & Wellness Counseling Association | Assistant Professor of Chia Nan University of Pharmacy & Science<br>Director of：<br>Harbinger VI Venture Capital Corp.<br>ScinoPharm Taiwan, Ltd.<br>Independent Director of：<br>Uni Pharma Co., Ltd | 109,539,014 |
| 1 | National Development Fund, Executive Yuan Representative: Ya-Po Yang | Ph.D. in Economics, Department of Economics National Taiwan University | Professor and Chairperson of Institute of Department of International Business, College of Business, Southern Taiwan University of Science and Technology | Professor of Institute of Business and Management, College of Management, National University of Kaohsiung<br>Director of：<br>ScinoPharm Taiwan, Ltd. | 109,539,014 |
| 2 | Taiwan Sugar Corporation Representative: Kuo-Hsi Wang | Ph.D. in Agricultural Chemistry, Department of Agricultural Chemistry National Taiwan University | Taiwan Sugar Corporation Chief，Deputy Chief Executive Officer，Institute Chair，Vice President | President of：<br>Taiwan Sugar Corporation<br>Director of：<br>ScinoPharm Taiwan, Ltd. | 32,581,963 |

Note : Shareholdings as of share transfer registration closing beginning on May 1st, 2021.

# ScinoPharm Taiwan, Ltd.
# Information of Independent Directors Nominees

| Name of Nominee | Academic Attainments | Past Career | Current Position | Amount of Shares Held (Unit: Share) [Note] | Serve as Independent Director for three consecutive terms |
|---|---|---|---|---|---|
| Lewis Lee | Master of Commerce, Department of Accounting, National Chengchi University | Deputy Chairman of PwC Taiwan | 1. Deputy Chairman, Zhi Cheng Co-Located CPA Firm<br>2. Adjunct Associate Professor, National Cheng Kung University<br>3. Independent director, Soft –World International Corp.(Note 2)<br>4. Independent director, Brogent Technologies Inc.<br>5. Independent director, All Ring Tech Co., Ltd.<br>6. Independent director, Poya International Co., Ltd.<br>7. Independent director, Xiamen Jinyuan President Securities Corp. Ltd. | 0 | No |
| Li-Tzong Chen | Ph.D, Kaohsiung Medical University Graduate Institute of Clinical Medicine | 1. Research Vice Superintendent, Kaohsiung Medical University Chung-Ho Memorial Hospital<br>2. Director, Cancer Center of Kaohsiung Medical University Chung-Ho Memorial Hospital<br>3. Acting Board Director of Taiwan Oncology Society<br>4. Acting Supervisor of The Gastroenterological Society of Taiwan<br>5. Deputy Chair of National Institute of Cancer Research, National Health Research Institutes<br>6. Adjunct Professor ,College of Medical Science and Technology, Taipei Medical University<br>7. Acting Director of Taiwan Pancreas Society<br>8. R&D consultant of Pharma Engine Inc. | 1. Distinguished Investigator & Director, National Institute of Cancer Research, National Health Research Institutes<br>2. President of Taiwan Oncology Society<br>3. Chair Professor , Internal Medicine, Kaohsiung Medical University<br>4. Emeritus Chair Professor of Institute of Biomedical Sciences, National Sun Yat-sen University<br>5. Adjunct Professor, Dept. Bio Science & Tech, National Yang Ming Chiao Tung University<br>6. Adjunct Attending Physician, Department of Internal Medicine, National Cheng-Kung University Hospital, Tainan<br>7. Professor, jointly appointed, Institute of Clinical Medicine, College of Medicine, NCKU<br>8. Professor, jointly appointed, Dept. of Internal Medicine, Clinical Medicine, NCKU<br>9. Professor, jointly appointed, Institute of Molecular Medicine, NCKU<br>10. Professor, jointly appointed, Institute of Clinical Pharmacy and Pharmaceutical Sciences, NCKU<br>11. Independent Director, ScinoPharm Taiwan, Ltd. | 0 | No |

| | | | | | |
|---|---|---|---|---|---|
| Wen-Chang Chang | Ph.D. Physiological Chemistry, University of Tokyo, Faculty of Pharmaceutical Sciences, Tokyo, Japan | 1. Vice Chairman, Institute for Biotechnology and Medicine Industry<br>2. Deputy Minister, National Science Council 、General Director, Department of Life Sciences, National Science Council, Taiwan<br>3. National Cheng Kung University, Tainan, Taiwan : Professor, Department of Pharmacology, College of Medicine 、Chairman, Department of Pharmacology, National Cheng Kung University 、Chairman, Institute of Basic Medical Sciences, National Cheng Kung University 、Associate Dean, College of Medical 、University Chair Professor 、Director, Center for Biosciences and Biotechnology、Dean, College of Bioscience and Biotechnology 、Distinguished Chair Professor 、Emeritus Distinguished Chair Professor | 1. Chairman, Board of Trustees, of Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University<br>2. Chair Professor, Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University<br>3. Emeritus Distinguished Chair Professor of National Cheng Kung University<br>4. Academician of Academia Sinica<br>5. Remuneration Committee member of Universal Cement Corporation<br>6. Independent Director, ScinoPharm Taiwan, Ltd. | 0 | No |

Note 1: Shareholdings as of share transfer registration closing beginning on May 1st, 2021.
Note 2: Tenure will end on June 13th 2021.

## Appendix 9

**Details of the Duties subject to releasing directors and independent Directors Candidates from Non-competition**

| Name | Current Position with Other Company |
|---|---|
| Uni-President Enterprises Corp. Representative Chih-Hsien Lo | **Chairman of：** Uni-President Enterprises Corp., President Natural Industrial Corp., Ton Yi Industrial Corp., Ttet Union Corporation, Prince Housing & Development Corp., President Packaging Industrial Corp., Woongjin Foods Co., Ltd., Daeyoung Foods Co., Ltd., President International Development Corp., Uni-President China Holdings Ltd., Changjiagang President Nisshin Food Co., Ltd., Uni-President (Philippines) Corp., Uni-President (Thailand) Ltd., Uni-President (Vietnam) Co., Ltd., Uni-President Enterprises (China) Investment Co., Ltd., President Chain Store Corp., Uni-President Cold-Chain Corp., Presco Netmarketing, Inc., Uni-President Dream Parks Co., President Century Corp., President Property Corp., Nanlien International Corp., Cheng-Shi Investment Holding Co., Prince Real Estate Co., Times Square International Holding Co., Times Square International Hotel Co., Times Square International Stays Co., Uni-President Express Corp.<br>**Vice Chairman of：** President Nisshin Corp.<br>**Director of：**<br>Presicarre Corp., Uni-Wonder Corp., Uni-President Organics Corp., Uni-President Glass Industrial Co., Ltd., Cayman President Holdings Ltd., Kai Yu (BVI) Investment Co., Ltd., President Fair Development Corp., Uni-President Southeast Asia Holdings Ltd., Uni-President Asia Holdings Ltd., Uni-President Hong Kong Holdings Ltd., Champ Green Capital Co., Ltd., Champ Green (Shanghai) Consulting Co., Ltd., Uni-President Enterprises (Guangzhou) Co., Ltd., 、Uni-President Enterprises (Fuzhou) Co., Ltd., Uni-President Enterprises (Xinjiang) Food Co., Ltd., Uni-President Enterprises (Wuhan) Food Co., Ltd., Uni-President Enterprises (Kunshan) Food Co., Ltd., Uni-President Enterprises (Chengdu) Food Co., Ltd., Uni-President Enterprises (Shenyang) Co., Ltd., Uni-President Enterprises (Harbin) Co., Ltd., Uni-President Enterprises (Hefei) Co., Ltd., Uni-President Enterprises (Zhengzhou) Co., Ltd., Uni-President Enterprises (Beijing) Drink Co., Ltd., Uni-Presodent Enterprises (Kunshan) Food Technology Co., Ltd., Uni-President Enterprises (Nanchang) Co.,Ltd., Uni-President (Shanghai) Trading Co., Ltd., Uni-President Enterprises (Kunming) Food Co., Ltd., Uni-Yantai Tongli Beverage Industries Co., Ltd., Uni-President Enterprises (Changsha) Co., Ltd., Uni-President (Bama) Mineral Water Co., Ltd., Uni-President Enterprises (Nanning) Co., Ltd., Uni-President Enterprises (Zhanjiang) Co., Ltd., Uni-President Enterprises (Chongqing) Co., Ltd., Uni-President Enterprises (Taizhou) Co., Ltd., Uni-President Enterprises (Akesu) Co., Ltd., Uni-President Enterprises (Changchun) Co., Ltd., Uni-President (Shanghai) Pearly Century Co., Ltd., Uni-President Enterprises (Baiyin) Co., Ltd., Hainan President Enterprises Co., Ltd., Uni-President Enterprises (Guiyang) Co., Ltd., Uni-President Enterprises (Jinan) Co., Ltd., Uni-President Enterprises (Hangzhou) Co., Ltd., Uni-President Enterprises |

| Name | Current Position with Other Company |
| --- | --- |
| | (Wuxue) Mineral Water Co., Ltd., Shijiazhuang President Enterprises Co., Ltd., Uni-President Enterprises (Xuzhou) Co., Ltd., Uni-President Enterprises (Henan) Co., Ltd., Uni-President Trading (Kunshan) Co., Ltd., Uni-President Enterprises (Shaanxi) Co., Ltd.、Uni-President Enterprises (Jiangsu) Co., Ltd., Uni-President Enterprises (Changbai Mountain Jilin) Mineral Water Co., Ltd., Uni-President Enterprises (Ningxia) Co., Ltd., Uni-President Enterprises (Shanghai) Co., Ltd., Uni-President Enterprises (Inner Mongolia) Co., Ltd., Uni-President Enterprises (Shanxi) Co., Ltd., Uni-President Enterprise (Hutubi) Tomato Products Technology Co., Ltd., Uni-President Enterprises (Shanghai) Drink & Food Co., Ltd., Uni-President Enterprises (Tianjin) Co., Ltd., Uni-President Enterprises (Hunan) Co., Ltd., Uni-Oao Travel Service Corp., President Packaging Holdings Ltd., Kuang Chuan Dairy Co., Ltd., Kuang Chuan Foods Ltd., President Energy Development (Cayman Islands) Ltd., Uni-President Development Corp., President Professional Baseball Team Corp., Tait Marketing & Distribution Co., Ltd., Wei Lih Food Industrial Co., Ltd., Keng Ting Enterprises Co., Ltd., President Chain Store (BVI) Holdings Ltd., President Chain Store (Labuan) Holdings Ltd., Rsi, Retail Support International Corp., Prince Property Management Consulting Co., Uni-President Assets Holdings Ltd., Kao Chuan Inv. Co., Ltd.<br>**Supervisor of**：<br>Infinity Holdings Ltd., Eternity Holdings Ltd.<br>**President of**：Presco Netmarketing Inc., Uni-President Express Corp. |
| Uni-President Enterprises Corp. Representative: Tsung-Ming Su | **Chairman of**：<br>President Life Sciences Co., Ltd., Tong Yu Investment Corp. Uni-President Development Corp., AndroSciences Corp.<br>**Director of**：<br>President Chain Store Corp., Grand Bills Finance Corp., President International Development Corp., Uni-President China Holdings Ltd. President Tokyo Corp., Uni-President Hong Kong Holdings Limited, Ltd., President Tokyo Auto Leasing Corp., Ltd., Tong Sheng (Suzhou) Car Rental Co., Ltd., Xiang Lu Industrial Ltd.,<br>President (BVI) International Investment Holdings Ltd., President Energy Development (Cayman Islands) Ltd., President Life Sciences Cayman Co., Ltd., SPT International, Tanvex Biologics, Inc.<br>**Supervisor of**：<br>Presicarre Corp., Uni-President Enterprises (China) Investment Co., Ltd., Presco Netmarketing Inc.<br>**President of**：<br>President International Development Corp., President Property Corp. |
| Kao Chyuan Inv. Corp. Representative: Shiow-Ling Kao | **Chairman of**：<br>Infinity Holdings Ltd., Eternity Holdings Ltd., President Fair Development Corp., Uni-President Department Store Corp., President Being Corp., President Pharmaceutical Corp., President Drugstore Business Corp., Kao Chuan Inv. Co., Ltd. |

| Name | Current Position with Other Company |
|---|---|
| | **Director of**：<br>Uni-President Enterprises Corp., Uni-Wonder Corp., Ton Yi Industrial Corp., Prince Housing & Development Corp., President International Development Corp., President Chain Store Corp., President Century Corp., Uni-President Development Corp., President (Shanghai) Health Product Trading Co., Ltd.,Beauty Wonder (Zhejiang) Trading Co. ,Ltd., Times Square International Holding Co.,<br>Times Square International Hotel Co.<br>**President of**： President Fair Development Corp.、Kao Chuan Inv. Co., Ltd. |
| Tainan Spinning Co., Ltd. Representative: Po-Ming Hou | **Chairman of**：<br>Tainan Spinning Co., Ltd., Tainan Spinning Retail & Distribution Co., Ltd., Tainan Spinning Co., Ltd.(Vietnam), Nan-Fan International Investment (Cayman), Ltd., Tainan Textile Co., Ltd., Yu Peng Investment Co., ltd., New Yupeng Investment Co., Ltd., Tainan Spinning Cultural and Educational Foundation.<br>**Director of**：<br>Nanfang Development Co., Ltd., Tainan Spinning Holdings (Cayman Islands) Co., Ltd., Prince Housing & Development Corp., Uni-President Enterprises Corp., President International Development Corp., Nantex Industry Co., Ltd., T. G. I. Co., Ltd., President Real Estate(U.S.) Investment Co, Nan Tai Royal Co., Ltd. |
| Uni-President Enterprises Corp. Representative: Tsung-Pin Wu | **Chairman of**：<br>Tung –Ren Pharmaceutical Corp., Kai Nan Investment Co.,<br>**Director of**：<br>President Chain Store Corp., Prince Housing & Development Corp., President Fair Development Corp., Uni-President (Vietnam) Co., Ltd., Uni-President Hong Kong Holdings Ltd., Kuang Chuan Dairy Co., Ltd., Kuang Chuan Foods Ltd., Tung Lo Development Co., Ltd., Tone Sang Construction Corp., Prince Real Estate Co., Times Square International Holding Co., Times Square International Hotel Co. Cheng-Shi Investment Holding Co.<br>**Supervisor of**：<br>President Kikkoman Inc., President International Development Corp., President Century Corp., President Professional Baseball Team Corp., Mean Time Enterprise Co., Nanlien International Corp., Times Square International Stays Co., Woongjin Foods Co., Ltd., Daeyoung Foods Co., Ltd., Uni-President Express Corp. Kunshan President Kikkoman Biotechnology Co., Ltd., President Kikkoman Zhenji Foods Co., Ltd., Ltd., |
| Uni-President Enterprises Corp. Representative: Chin-Yuan Cheng | **Chairman of**：Jin-Guan-Cheng Corp. |

| Name | Current Position with Other Company |
|---|---|
| Uni-President Enterprises Corp. Representative: Jia-Horng Guo | **Vice Chairman of：** Taishin Securities Co., Ltd.<br>**Supervisor of :** Standard Motor Corp., Dynasty Techwood Corp. |
| President International Development Corp. | **Chairman of：** President Life Sciences Co., Ltd., AndroSciences Corp.<br>**Director of：**<br>Allianz Pharmascience Ltd., Helios Bioelectronics Inc., Dabomb Protein Corp., RenalPro Medical, Inc. |
| President International Development Corp. Representative: Chiou-Ru Shih | **Director of：**<br>SyNergy ScienTech Corp., President Life Sciences Cayman Co., Ltd., Grand Bills Finance Corp., Helios Bioelectronics Inc., Dabomb Protein Corp., IMQ Technology Inc.<br>**Vice President of：** President International Development Corp. |
| National Development Fund, Executive Yuan | **Director of：**<br>Genovate Biotechnology Co., Taiwan Biotech Co., Ltd., Taiwan Flower Biotechnology Co., Ltd., United Biomedical Inc. (Asia), Adimmune Corp., TaiGen Biopharmaceuticals Holdings Ltd., PharmaEssentia Corp., PharmaEngine Inc., TaiAn Technologies Corp., TaiMed Biologics Inc., EirGenix Inc., MetaTech Inc., Apex Medical Corp.<br>Point Robotics MedTech Inc. |
| National Development Fund, Executive Yuan Representative: Ming-Chuan Hsieh | **Director of：**<br>Harbinger VI Venture Capital Corp.,<br>**Independent Director of：** Uni Pharma Co., Ltd<br>**Supervisor of：** Han Tong Investment Inc.,<br>Harbinger VIII Venture Capital Corp.,<br>**Remuneration Committee member of：** PharmaEssentia Corp. |
| Taiwan Sugar Corp. | Taiwan Sugar Corp.<br>**Director of：**<br>United Biomedical Inc. (Asia), TaiGen Biopharmaceuticals Holdings Ltd. |
| Taiwan Sugar Corp. Representative: Kuo-Hsi Wang | **Vice President of：** Taiwan Sugar Corp.<br>**Director of：** United Biomedical Inc. (Asia), TaiGen biotechnology Co., Ltd. |
| Lewis Lee | **Independent Director of：**<br>Brogent Technologies Inc., All Ring Tech Co., Ltd.,<br>Poya International Co., Ltd. Jin Yuan President Securities Corporation Limited. |
| Wen-Chang Chang | **Chairman of：** Taipei Medical University<br>**Remuneration Committee member of：** Universal Cement Corp. |